NCT01052662

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 87 (actual)
• Sponsor: University of Massachusetts, Worcester · Academic / Other
• Sex: All
• Age: 18 Years – 25 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the effect of memantine and buprenorphine on opioid abusing behavior, to determine the effect of memantine and buprenorphine on early relapse and to evaluate the tolerability of memantine co-administrated with buprenorphine. The study seeks to determine if combined treatment of memantine and buprenorphine may provide shorter-term treatment for opioid dependence.

Detailed description

Opiate dependence is an increasing problem among young adults (18-25 years old) whose rates of current use of illicit drugs are generally high (19.7 %)according to data from the 2007 National Survey on Drug Use \& Health (Substance Abuse and Mental Health Services Administration 2008). Young adults start using heroin around this age range, and more recently have had increasing rates of prescription-type drug use. Given that young adults with opiate dependence who are seeking treatment are relatively treatment naïve, have a shorter period of addiction, and are more likely to choose buprenorphine over methadone, developing short-term buprenorphine treatment alternatives to long-term methadone agonist treatment is needed.

Conditions

• Opioid Dependence

Interventions

Type	Name	Description
DRUG	Memantine	30mg/day Memantine orally everyday for 12 weeks
DRUG	Memantine	15 mg/day Memantine orally everyday for 12 weeks
DRUG	Placebo	Placebo orally everyday for 12 weeks

Timeline

• Start date: 2009-10-01
• Primary completion: 2013-06-01
• Completion: 2013-10-01
• First posted: 2010-01-20
• Last updated: 2015-04-01
• Results posted: 2015-03-06

Locations

1 site across 1 country: United States